Alain Frédéric Carpentier (born 11 August 1933) is a French
surgeon whom the President of the
American Association for Thoracic Surgery calls the father of modern
mitral valve repair. He is most well known for the development and popularization of a number of mitral valve repair techniques. In 1996, he performed the first minimally invasive
mitral valve repair in the world and in 1998 he performed the first robotic
mitral valve repair with the DaVinci robot prototype.[1] He is the recipient of the 2007
Lasker Prize.
Carpentier is a member of the
French Academy of Sciences and sits on the
Board of Directors of the
World Heart Foundation. The recipient of numerous awards, including the 1996
Prix mondial Cino Del Duca, in 2005 the
American Association for Thoracic Surgery (AATS) bestowed its Medallion for Scientific Achievement for only the fifth time in its history. In announcing Carpentier as the recipient, the AATS also noted that he is "one of the foremost medical
philanthropists in the world, having established a premier cardiac center in
Vietnam a decade ago where over 1,000 open-heart cases are now performed annually. In addition, he has founded cardiac surgery programs in 17 French-speaking countries in Africa."
In October 2001 he received an Honorary Doctor of Medicine and Surgery degree from
University of Pavia.[3]
In 2006, Carpentier received considerable media attention in the United States as the surgeon who performed an emergency mitral valve repair procedure on
Charlie Rose when the
PBS television interviewer fell ill while en route to
Damascus to interview
Syrian President
Bashar al-Assad.
In 1989, Carpentier pioneered work to use the patient's own
skeletal muscle (the latimissus dorsi muscle) to repair the failing myocardium, a procedure known as
cardiomyoplasty, which has since advanced into the exciting realms of tissue engineering science.[4][5] In 2008, Carpentier announced a fully implantable
artificial heart will be ready for clinical trial by 2011, and for alternative to transplant in 2013. It was developed and will be manufactured by him, Biomedical firm Carmat, and venture capital firm
Truffle. The prototype uses electronic sensors and is made from chemically treated animal tissues, called "biomaterials," or a "pseudo-skin" of biosynthetic, microporous materials, amid another US team's prototype called 2005 MagScrew Total Artificial Heart, and Japan and South Korea researchers are racing to produce similar projects.[6][7] The first clinical trial are under process since 2013.
Alain Carpentier, David Adams and Farzan Filsoufi (2010). Carpentier's reconstructive valve surgery. Missouri: Saunders Elsevier. 368 pp.
ISBN9780721691688. Illustrated by Alain Carpentier and Marcia Williams.
Chauvaud S, Carpentier A (June 2008). "Ebstein's anomaly: the Broussais approach". Multimedia Manual of Cardio-Thoracic Surgery. 74 (2): 438–43.
doi:
10.1510/mmcts.2007.003038.
PMID24415583.
Cortes-Morichetti M, Frati G, Schussler O, et al. (November 2007). "Association between a cell-seeded collagen matrix and
cellular cardiomyoplasty for myocardial support and regeneration". Tissue Engineering. 13 (11): 2681–7.
doi:
10.1089/ten.2006.0447.
PMID17691866.
Chachques JC, Azarine A, Mousseaux E, El Serafi M, Cortes-Morichetti M, Carpentier AF (June 2007). "MRI evaluation of local myocardial treatments: epicardial versus endocardial (Cell-Fix catheter) injections". Journal of Interventional Cardiology. 20 (3): 188–96.
doi:
10.1111/j.1540-8183.2007.00255.x.
PMID17524110.
Martinod E, Seguin A, Holder-Espinasse M, et al. (March 2005). "Tracheal regeneration following tracheal replacement with an allogenic aorta". The Annals of Thoracic Surgery. 79 (3): 942–8, discussion 949.
doi:
10.1016/j.athoracsur.2004.08.035.
PMID15734409.
Martinod E, Seguin A, Pfeuty K, et al. (May 2003). "Long-term evaluation of the replacement of the trachea with an autologous aortic graft". The Annals of Thoracic Surgery. 75 (5): 1572–8, discussion 1578.
doi:
10.1016/S0003-4975(03)00120-6.
PMID12735581.